| |
|
|
Forskning
Vi samarbejder med Aalborg Universitet, Esbjerg og flere internationale forskningscentre.
Publicerede videnskabelige artikler fra 2005:
 85. Haga H-J, Gjesdal CG, Irgens LM, ôstensen M: Reproduction and gynecological disease in women with primary Sjögren’s syndrome.
A case control study.
Scand J Rheumatology 2005; 34: 45-48.
86. Rødevand E, Mikkelsen K, Nordvås BY, Haga H-J, Førre Ø, Johnsen V, Kvien T:
Medikamentell profylakse og behandling av steroidindusert osteoporose.
Journal of the Norwegian Medical Association 2005; 125:1643-5.
87. Haga H-J: TNF-alfa-hemmere øker risikoen for lymfom.
Journal of the Norwegian Medical Association 2005; 125: 1623.
88. Haga H-J, Gjesdal CG, Koksvik HS, Skomsvoll JF, Irgens L, Østensen M:
Pregnancy outcome in patients with primary Sjögren’s syndrome.
Journal of Rheumatology 2005; 32(9): 1734-36.
89. Haga H-J: Øker TNF-alfa hemmere risikoen for lymfom?
Journal of the Norwegian Medical Association 2005; 22: 3075.
90. Cervera R et.al.: Systemic Lupus Erythematosus in Europe at the change of the millenium: Lesson from the “Euro-lupus Project”
Autoimmunity Reviews 2006; 5:180-186.
91. Haga H-J. Nytt I behandlingen av Systemisk lupus erythematosus.
Revmatikeren 2006; 3: 16.
92. Haga H-J: Bruk av blodprøver I diagnostikk av reumatiske sykdommer.
Utposten 2006; 6: 26-29.
93. Haga H-J, Peen E: A study of the arthritis pattern in Primary Sjögren’s syndrome.
Clinical and Experimental Rheumatology 2007; 25:88-91.
94. Haga H-J: Abatacept – et nytt prinsipp I behandlingen af Rheumatoid arthrit.
ReumaDebat september 2007 28-29.
95. Hjardem E, Østergaard M, Pødenphant J, Tarp U, Smedegaard Andersen L, Bing J, Peen E, et.al.:
Do Rheumatoid Arthritis Patients in clinical practice benefit from switching from Infliximab to a second tumor necrosis factor alpha inhibitor?
Ann Rheum Dis 2007; 66 (9): 1184-89.
96. Julsrud Haugen A, Peen E, Hulten B, Johannessen AC, Halse AK, Haga H-J: Estimation of the prevalence of primary Sjögren’s syndrome in two age-different community-based populations using two sets of classification criteria.
The Hordaland Health Study.
Scandinavian Journal of Rheumatology 2008; Jan-Feb: 37(1): 30-34. .
97. Haga H-J, EM Jacobsen, Peen E: Incidence of thromboembolic events in patients with primary Sjögren’s syndrome.
Scandinavian Journal of Rheumatology 2008; March-April, 37(2): 127-9.
98. Peen E, Haugen AJ, GE Kahrs, Haugen M, Haga H-J: The effect of liquid diet on salivary flow in primary Sjögren’s syndrome.
Scandinavian Journal of Rheumatology 2008; 37(3): 236.
99 . Peen E, Mellbye O, Haga H-J: IgA Rheumatoid Factor in primary Sjögren’s syndrome.
Scandinavian Journal of Rheumatology 2009; 38(1):46-49
100. Haga H-J, Alsnes R: Ny behandling av artrose?
Reumatikeren 2008; 8:18-19. .
101. Kassetænkning frem for lægefaglighed. Best Practice nr.4 aprol 2009 side 16-17.
102. Haga H-J: Sjögrens syndrom.
Best Practice nr.10 septemberv 2010, side 33-36
103. Peen E, Haga H-J: IgA Rheumatoid faktor og primært Sjögrens syndrom.
Best Practice nr.11 2010: side 5
104. Haga H-J: Sjögrens syndrom.
Best Practice nr.11 2010: side 29.
105. Haga H-J, Terp Andersen D, Peen E: Prevalence of IgA class antibodies to cyclic citrullinated peptide (anti-CCP) in patients with primary Sjögren's syndrome, and its association to clinical manifestations.
Clin Rheumatol 2011;30: 369-372
106. Haga H-J, Andersen D T, Peen E:
Prevalence of IgA class antibodies to cyclic citrullinated peptide (anti-CCP) in patients with primary Sjögren's syndrome, and its association to clinical manifestations.
Clinical Rheumatologfy 2011; 30:(3):369-372.
|
|
| |
| |
